文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

ADMET 2:哌甲酯治疗阿尔茨海默病淡漠的III期随机对照试验方案

The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-01-18

ADMET 2是一项III期、安慰剂对照、设盲、为期6个月的多中心随机临床试验,计划纳入200例阿尔茨海默病伴淡漠患者,按1:1随机分配至每日20 mg哌甲酯组或匹配安慰剂组。主要结局为神经精神量表淡漠亚量表评分从基线至6个月的变化均差,以及第6个月修改版AD协作研究临床总体印象变化评分达到特定等级或以上的比值比。该试验基于原ADMET试验的积极结果,以更大样本量和更长随访确认或否定原发现。

要点

  • ADMET 2为III期多中心随机对照试验,计划纳入200例AD伴淡漠患者。
  • 干预为每日20 mg哌甲酯(四片过封装片)或匹配安慰剂,1:1随机分组。
  • 主要结局为6个月时NPI淡漠亚量表评分变化均差及mADCS-CGIC评分的比值比。

核心结论

  • ADMET 2旨在通过更大样本量和更长随访,确认或否定原ADMET试验关于哌甲酯治疗AD淡漠的发现。

研究设计与样本

  • III期、安慰剂对照、设盲、为期6个月的多中心随机临床试验,目标纳入200例AD伴淡漠患者,按1:1随机分配至每日20 mg哌甲酯组或匹配安慰剂组。

主要发现

  • 原ADMET试验(60例,随访6周)发现哌甲酯治疗AD淡漠在3项结局指标中的2项与显著改善相关,并有部分整体认知改善证据且不良事件极少。
  • ADMET 2的主要结局包括NPI淡漠亚量表评分从基线至6个月变化的均差,以及第6个月mADCS-CGIC评分达到特定等级或以上的比值比。
  • 其他结局包括认知变化、安全性和成本效果,在每月随访中评估至6个月。

关键数值与推荐

  • 干预:每日20 mg哌甲酯,配制成四片过封装片;对照为匹配安慰剂;随机比例1:1。
  • 主要结局1:NPI淡漠亚量表评分从基线至6个月变化的均差。
  • 主要结局2:第6个月mADCS-CGIC评分达到特定等级或以上(与基线评分相比)的比值比。

临床怎么用

  • 原文未报告临床实践推荐;该试验旨在评估哌甲酯治疗AD淡漠的疗效,结果待发表。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alzheimer's disease (AD) is characterized not only by cognitive and functional decline, but also often by the presence of neuropsychiatric symptoms. Apathy, which can be defined as a lack of motivation, is one of the most prevalent neuropsychiatric symptoms in AD and typically leads to a worse quality of life and greater burden for caregivers. Treatment options for apathy in AD are limited, but studies have examined the use of the amphetamine, methylphenidate. The Apathy in Dementia Methylphenidate Trial (ADMET) found that treatment of apathy in AD with methylphenidate was associated with significant improvement in apathy in two of three outcome measures, some evidence of improvement in global cognition, and minimal adverse events. However, the trial only enrolled 60 participants who were followed for only 6 weeks. A larger, longer-lasting trial is required to confirm these promising findings. METHODS: The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a phase III, placebo-controlled, masked, 6-month, multi-center, randomized clinical trial targeted to enroll 200 participants with AD and apathy. Participants are randomly assigned 1:1 to 20 mg methylphenidate per day prepared as four over-encapsulated tablets or to matching placebo. The primary outcomes include (1) the mean difference in the Neuropsychiatric Inventory Apathy subscale scores measured as change from baseline to 6 months, and (2) the odds of having a given rating or better on the modified AD Cooperative Study Clinical Global Impression of Change ratings at month 6 compared with the baseline rating. Other outcomes include change in cognition, safety, and cost-effectiveness measured at monthly follow-up visits up to 6 months. DISCUSSION: Given the prevalence of apathy in AD and its impact on both patients and caregivers, an intervention to alleviate apathy would be of great benefit to society. ADMET 2 follows on the promising results from the original ADMET to evaluate the efficacy of methylphenidate as a treatment for apathy in AD. With a larger sample size and longer follow up, ADMET 2 is poised to confirm or refute the original ADMET findings. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02346201 . Registered on 26 January 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Scherer RW, Drye L, Mintzer J, et al. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29347996. doi:10.1186/s13063-017-2406-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。